Optimised compounds
US12195557B2 · kind B2 · utility
0Cited by
8References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 21, 2018 |
| Grant date | Jan 14, 2025 |
| Priority date | — |
| Expiry date | Sep 4, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/55511
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to TLR2 agonist compounds and their compositions, and the use of such compounds and compositions in the prevention and/or treatment of respiratory infections, or diseases or conditions associated with viral or bacterial infections.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.